Business Description
Rain Oncology Inc
NAICS : 541714
SIC : 2834
ISIN : US75082Q1058
Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.71 | |||||
| 9-Day RSI | 46.53 | |||||
| 14-Day RSI | 47.78 | |||||
| 6-1 Month Momentum % | -11.03 | |||||
| 12-1 Month Momentum % | -87.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-Forward-EBIT | -4.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RAIN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rain Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.06 | ||
| Beta | 0 | ||
| Volatility % | 98.35 | ||
| 14-Day RSI | 47.78 | ||
| 14-Day ATR ($) | 0.023374 | ||
| 20-Day SMA ($) | 1.2095 | ||
| 12-1 Month Momentum % | -87.9 | ||
| 52-Week Range ($) | 0.82 - 11.32 | ||
| Shares Outstanding (Mil) | 36.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rain Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rain Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rain Oncology Inc Frequently Asked Questions
What is Rain Oncology Inc(RAIN)'s stock price today?
The current price of RAIN is $1.21. The 52 week high of RAIN is $11.32 and 52 week low is $0.82.
When is next earnings date of Rain Oncology Inc(RAIN)?
The next earnings date of Rain Oncology Inc(RAIN) is 2025-03-08 Est..
Does Rain Oncology Inc(RAIN) pay dividends? If so, how much?
Rain Oncology Inc(RAIN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers